NEW YORK, March 27, 2012 /PRNewswire/ -- Islet Sciences, Inc., (OTC.BB: ISLT) a biotechnology company engaged in the research, development and commercialization of patented technologies in the

NEW YORK, Feb.

MIAMI, Oct.

A team of researchers from several collaborating Baylor University research centers and from Japan's Okayama Graduate School of Medicine have found a way to more consistently isolate pancreatic islet cells from brain dead donors using ductal injection (DI), a process that immediately cools donor islet cells at the injection site.

DiaKine Therapeutics, a development-stage company commercializing immune modulators for the treatment of diabetes and related complications, has announced that a Phase II clinical trial with the company's lead drug candidate, Lisofylline, is underway.